Guggenheim Reiterates Buy Rating on EyePoint, Inc. with $68 Target

Guggenheim reiterated its buy rating on EyePoint, Inc. (NasdaqGM:EYPT) and set a price target of $68 on June 24, 2026. The analyst Yatin Suneja expressed confidence in the company's prospects, and shares traded at $14.38 on Wednesday.

Other Institutional Activity in EyePoint, Inc.

Several institutional investors have adjusted their positions in EyePoint, Inc. Suvretta Capital Management increased its holdings by 468,690 shares, ending with 8,296,375 shares valued at about $106.9 million. BlackRock, Inc. also grew its stake by 389,465 shares, holding 7,177,337 shares worth approximately $92.5 million. Meanwhile, Federated Hermes, Inc. trimmed its position by 347,844 shares, resulting in 5,669,589 shares valued at $73.1 million. Franklin Resources Inc. added 71,683 shares to hold 5,048,598 shares worth roughly $65.1 million.

EyePoint, Inc. Stock Up 206.0%

Shares of EyePoint, Inc. traded near $14.38 on Wednesday. The company has a market cap of about $1.15 billion and a beta of 1.748, indicating moderate volatility compared to the market. The stock's 52-week range is between $7.94 and $19.11, with a 50-day moving average of $13.28 and a 200-day moving average of $14.10. EyePoint's current ratio stands at 6.66, and its quick ratio is 5.97, reflecting strong liquidity.

Recent Earnings

EyePoint, Inc. reported revenue of $7.61 million, with a revenue growth rate of 1.617. The company posted an EPS loss of $3.51, resulting in a negative return on equity of -102.71%. The net margin was reported at zero. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at EyePoint, Inc.

Recent insider activity at EyePoint, Inc. includes transactions by Chief Financial Officer George Elston, who sold 3,627 shares at $12.93 each on May 25, 2026, and bought 7,500 shares on the same day. Chief Medical Officer Ramiro Ribeiro sold 2,437 shares at $15.00 and bought the same amount at $8.26 on April 17, 2026.

Analysts Set New Price Targets

On June 24, 2026, Guggenheim reiterated its buy rating on EyePoint, Inc. with a $68 price target. RBC Capital maintained its buy rating with a target of $37 on May 7, 2026. Citigroup also maintained its buy rating with a target of $35 on March 9, 2026. The consensus among 12 analysts is a strong buy, with a mean price target of $37.

About EyePoint, Inc.

EyePoint, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing and commercializing treatments for serious retinal diseases. The company's main product candidate, DURAVYU, is in Phase 3 trials for conditions like wet age-related macular degeneration and diabetic macular edema. EyePoint leverages its Durasert E technology for sustained drug delivery. Led by CEO Dr. Jay S. Duker, the company has about 214 employees.

Bottom Line

Guggenheim's reiterated buy rating and $68 price target reflect confidence in EyePoint, Inc.'s potential, even as the stock trades well below this target. Investors watch these ratings closely as they provide insight into analyst expectations. It's important to remember that analyst ratings are one of many factors investors consider when evaluating a stock.